Experimental melanoma cocktail trial halted early
NCT ID NCT03958383
First seen Jun 13, 2026 · Last updated Jun 13, 2026
Summary
This early-stage trial tested a combination of an experimental fusion protein (hu14.18-IL2), radiation, and two immunotherapy drugs (nivolumab and ipilimumab) in people with advanced melanoma that couldn't be surgically removed. The goal was to find the safest dose and check for side effects. The study was terminated early after enrolling only 8 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.